This site is intended for healthcare professionals

CHMP recommends change to authorisation for Briviact in partial onset seizures.- UCB

Read time: 1 mins
Published:29th Jan 2022
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Briviact (brivaracetam) from UCB Pharma.

The CHMP adopted an extension to the existing indication as follows: Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

Condition: Epilepsy
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.